---
document_datetime: 2025-03-28 15:50:39
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ontilyv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ontilyv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9840117
conversion_datetime: 2025-12-23 03:56:32.483249
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                      | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2702              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC in order to add 'fall' and 'fatigue' to the list of adverse drug reactions | 11/07/2024                                  |                                             | SmPC and PL                      | Please refer to the Scientific Discussion in this AR. As a result of this variation, section 4.8 of the SmPC is updated in order to add 'fall' and 'fatigue' to the list of adverse drug reactions (ADRs) with frequency uncommon, based on the analysis of safety data from the integrated safety information from all completed clinical studies and |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Ontilyv Procedural steps taken and scientific information after the authorisation Application number Commission Decision Issued 2 / amended Product Information affected 3 Summary WS/2702 SmPC and PL Please refer to the Scientific Discussion in this AR. As a result of this variation, section 4.8 of the SmPC is updated in order to add 'fall' and 'fatigue' to the list of based on the analysis of safety data from the integrated safety information from all completed clinical studies and Medicinal product no longer authorised

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | (ADRs) with frequency uncommon based on the cumulative review of literature. The Package Leaflet is updated accordingly. The Ongentys RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template version 10.4 and to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | the post-market surveillance information over six years of worldwide marketing exposure. The Package Leaflet is updated accordingly. The MAH took also the opportunity to update the list of local representatives in the PL, bring the product information in line with the latest QRD template version 10.4 and to introduce minor editorial changes in the PI. For more information, please refer to the SmPC. authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1748/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place product                                                                                                                                                                    | 16/05/2024 n/a no longer                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/2666/G | This was an application for a group of variations following a worksharing Article 20 of Commission 1234/2008. B.I.a.1.f - Change starting material/reagent/intermediate Changes to quality Medicinal                                                                                                                                                                                                                                                                                                                                   | 21/03/2024 n/a                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                               |                   | authorised   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------|
| IG/1702   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                         | 15/01/2024        | n/a          |
| IG/1694   | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                 | 08/12/2023        | n/a longer   |
| WS/2589   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data product | 23/11/2023 n/a no | n/a          |
| WS/2542/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting Medicinal                                                                        | 12/10/2023        |              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1646   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient 02/08/2023 no                                                                                                                                                                                                                                                                                                                            |
| WS/2455/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting 26/04/2023 Medicinal product                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place authorised                                                                                                                                                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2417/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation 16/03/2023 n/a Medicinal product no longer |

<div style=\"page-break-after: always\"></div>

| IG/1595   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or excipient                                                                                                    | 13/02/2023   | n/a            | manufacturer of a novel   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------|---------------------------|
| IG/1586   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                     | 06/01/2023   | n/a authorised |                           |
| IG/1571   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                            | 11/11/2022   | n/a longer     |                           |
| WS/2348   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time product | 10/11/2022   | n/a no         | data                      |
| IG/1562   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                    | 31/10/2022   | n/a            | Medicinal                 |
| WS/2332/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                 | 22/09/2022   | n/a            |                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0006   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                            | 24/08/2022   | 17/07/2023   | SmPC and PL   | To update section 4.8 of the SmPC and section 4 of the PL to add 'nausea' with a frequency 'common' to implement the wording agreed by the CHMP and to update section 4.4 of the SmPC and section 2 of the PL to include the statement related to the excipient sodium, in alignment with the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (EMA/CHMP/302620/2017 Rev. 1*) authorised   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2295   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                      | 14/07/2022   | n/a no       | longer        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IG/1516/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation Medicinal product | 25/05/2022   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IG/1507/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                        | 19/04/2022   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->